The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Open accessAbstract
Inherited and somatic mutations in the adenomatous polyposis coli occur in most colon cancers, leading to activation of β-catenin-responsive genes. To identify small molecule antagonists of this pathway, we challenged transformed colorectal cells with a secondary structure-templated chemical library, looking for compounds that inhibit a β-catenin-responsive reporter. We identified ICG-001, a small molecule that down-regulates β-catenin/T cell factor signaling by specifically binding to cyclic AMP response element-binding protein. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, G., Adida, C., & Altieri, D. C. (1997) · Nature Medicine · doi:10.1038/nm0897-917 · Cited by 3,165
Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
MECHANISMS OF WNT SIGNALING IN DEVELOPMENT
Wodarz, A., & Nusse, R. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.59 · Cited by 2,017
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Tamm, I., Wang, Y., Sausville, E. A., Scudiero, D. A., Vigna, N. J., Oltersdorf, T., & Reed, J. C. (1998) · PubMed · Cited by 1,244
The Promise and Perils of Wnt Signaling Through β-Catenin
Moon, R. T., Bowerman, B., Boutros, M., & Perrimon, N. (2002) · Science · doi:10.1126/science.1071549 · Cited by 969
Self-citationHuber, A. H., & Weis, W. I. (2001) · Cell · doi:10.1016/s0092-8674(01)00330-0 · Cited by 777
Cited by
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Self-citationTargeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Tackling the cancer stem cells — what challenges do they pose?
Pattabiraman, D. R., & Weinberg, R. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4253 · Cited by 990
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2137 · Cited by 841
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743
Seino, T., Kawasaki, S., Shimokawa, M., Tamagawa, H., Toshimitsu, K., Fujii, M., Ohta, Y., Matano, M., Nanki, K., Kawasaki, K., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.12.009 · Cited by 631
The regulation of β-catenin activity and function in cancer: therapeutic opportunities
Shang, S., Hua, F., & Hu, Z.-W. (2017) · Oncotarget · doi:10.18632/oncotarget.15687 · Cited by 641
Protein Lysine Acetylation by p300/CBP
Dancy, B. M., & Cole, P. A. (2015) · Chemical Reviews · doi:10.1021/cr500452k · Cited by 609
WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells
Woodward, W. A., Chen, M. S., Behbod, F., Alfaro, M. P., Buchholz, T. A., & Rosen, J. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606599104 · Cited by 603
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
The Wnt signaling pathway in cancer
Duchartre, Y., Kim, Y.-M., & Kahn, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.005 · Cited by 548
Self-citationId family of helix-loop-helix proteins in cancer
Perk, J., Iavarone, A., & Benezra, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1673 · Cited by 535
Bochet, L., Lehuédé, C., Dauvillier, S., Wang, Y. Y., Dirat, B., Laurent, V., Dray, C., Guiet, R., Maridonneau-Parini, I., Le Gonidec, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0530 · Cited by 529
Wnt/β-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome
Khramtsov, A. I., Khramtsova, G. F., Tretiakova, M., Huo, D., Olopade, O. I., & Goss, K. H. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091125 · Cited by 509
Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Takahashi-Yanaga, F., & Kahn, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2943 · Cited by 499
Self-citationβ-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis
Monga, S. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.056 · Cited by 487
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
White, B. D., Chien, A. J., & Dawson, D. W. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.001 · Cited by 469
Inhibition of Wnt/β-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis
Henderson, W. R., Chi, E. Y., Ye, X., Nguyen, C., Tien, Y.-T., Zhou, B., Borok, Z., Knight, D. A., & Kahn, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001520107 · Cited by 462
Self-citationTarget deconvolution strategies in drug discovery
Terstappen, G. C., Schlüpen, C., Raggiaschi, R., & Gaviraghi, G. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2410 · Cited by 429
Lu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine · doi:10.1038/nm.4424 · Cited by 425
Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer
Cheng, X., Xu, X., Chen, D., Zhao, F., & Wang, W. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.082 · Cited by 417
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 391
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
WNT signalling in prostate cancer
Murillo-Garzón, V., & Kypta, R. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.144 · Cited by 361
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
Madan, B., Ke, Z., Harmston, N., Ho, S. Y., Frois, A. O., Alam, J., Jeyaraj, D. A., Pendharkar, V, Ghosh, K., Virshup, I. H., et al. (2016) · Oncogene · doi:10.1038/onc.2015.280 · Cited by 341
Novellasdemunt, L., Antas, P., & Li, V. S. W. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00117.2015 · Cited by 339
Waaler, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., Wilson, S. R., Paulsen, J. E., Pedersen, N. M., Eide, T. J., Machonova, O., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3336 · Cited by 328
Wu, R., Hendrix-Lucas, N., Kuick, R., Zhai, Y., Schwartz, D. R., Akyol, A., Hanash, S., Misek, D. E., Katabuchi, H., Williams, B. O., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.016 · Cited by 313
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Wnt/β-catenin/CBP signaling maintains long-term murine embryonic stem cell pluripotency
Miyabayashi, T., Teo, J.-L., Yamamoto, M., McMillan, M., Nguyen, C., & Kahn, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701331104 · Cited by 310
Self-citationMa, H., Nguyen, C., Lee, K.-S., & Kahn, M. (2005) · Oncogene · doi:10.1038/sj.onc.1208433 · Cited by 307
Self-citationβ-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Walsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Pez, F., Lopez, A., Kim, M., Wands, J. R., Caron de Fromentel, C., & Merle, P. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.001 · Cited by 294
WNT Signaling and Colorectal Cancer
Schatoff, E. M., Leach, B. I., & Dow, L. E. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0354-9 · Cited by 293
Li, L., & Bhatia, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1499 · Cited by 293
Hepatocellular Carcinoma: Molecular Pathways and New Therapeutic Targets
Roberts, L. R., & Gores, G. J. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871200 · Cited by 289
Mediator Is a Transducer of Wnt/β-Catenin Signaling
Kim, S., Xu, X., Hecht, A., & Boyer, T. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602696200 · Cited by 288
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Wnt/β-catenin signalling in prostate cancer
Kypta, R. M., & Waxman, J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.116 · Cited by 275
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J.-K., Ahn, S. H., Lee, J., & Nam, D.-H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 273
Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin
Grossmann, T. N., Yeh, J. T.-H., Bowman, B. R., Chu, Q., Moellering, R. E., & Verdine, G. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208396109 · Cited by 268
Zhou, B., Liu, Y., Kahn, M., Ann, D. K., Han, A., Wang, H., Nguyen, C., Flodby, P., Zhong, Q., Krishnaveni, M. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276311 · Cited by 261
Self-citationTargeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Hammitzsch, A., Tallant, C., Fedorov, O., O’Mahony, A., Brennan, P. E., Hay, D. A., Martinez, F. O., Al-Mossawi, M. H., de Wit, J., Vecellio, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501956112 · Cited by 254
Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
A complex task? Direct modulation of transcription factors with small molecules
Koehler, A. N. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.022 · Cited by 189
Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
van Andel, H., Kocemba, K. A., Spaargaren, M., & Pals, S. T. (2019) · Leukemia · doi:10.1038/s41375-019-0404-1 · Cited by 188
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
TNIK inhibition abrogates colorectal cancer stemness
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12586 · Cited by 168
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Wnt/β-Catenin Signaling in Liver Cancers
Wang, W., Smits, R., Hao, H., & He, C. (2019) · Cancers · doi:10.3390/cancers11070926 · Cited by 143
Dietrich, L., Rathmer, B., Ewan, K., Bange, T., Heinrichs, S., Dale, T. C., Schade, D., & Grossmann, T. N. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.013 · Cited by 126
Protein–protein interactions as targets for small-molecule therapeutics in cancer
White, A. W., Westwell, A. D., & Brahemi, G. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000641 · Cited by 122
Chen, G., Gao, C., Gao, X., Zhang, D. H., Kuan, S.-F., Burns, T. F., & Hu, J. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0561 · Cited by 104
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Redox Control of the Senescence Regulator Interleukin-1α and the Secretory Phenotype
McCarthy, D. A., Clark, R. R., Bartling, T. R., Trebak, M., & Melendez, J. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.493841 · Cited by 73
Lafyatis, R., Mantero, J. C., Gordon, J., Kishore, N., Carns, M., Dittrich, H., Spiera, R., Simms, R. W., & Varga, J. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.06.032 · Cited by 59
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers · doi:10.3390/cancers10040095 · Cited by 51
“We have previously demonstrated that survivin, the number 4 transcript up-regulated in cancer [30], is a Wnt/CBP/β-catenin target in colorectal cancer cells and colorectal cancer patient circulating tumor cells [25,31] and its expression is decreased upon treatment with specific CBP/β-catenin antagonists.”
BackgroundMethodResultInfluentialSelf-citationHahne, G., & Grossmann, T. N. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.050 · Cited by 46
Kinetics of Wnt-driven β-catenin stabilization revealed by quantitative and temporal imaging
Hannoush, R. N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003498 · Cited by 42
Hennig, K. M., Fass, D. M., Zhao, W.-N., Sheridan, S. D., Fu, T., Erdin, S., Stortchevoi, A., Lucente, D., Cody, J. D., Sweetser, D., et al. (2017) · Complex Psychiatry · doi:10.1159/000475666 · Cited by 36
Nasser, F., Moussa, N., Helmy, M. W., & Haroun, M. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01988-x · Cited by 29
Kim, J., Jeon, Y. J., Chang, I.-Y., Lee, J.-H., & You, H. J. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01381-1 · Cited by 4
Metadata
- Authors
- Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., Moon, S. H., Ha, J. R., & Kahn, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-08-16
- Volume
- 101
- Issue
- 34
- Pages
- 12682-12687
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2115001053
- Cited by
- 874
- References
- 43
- FWCI
- 6.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.